Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment.

Nab‐Paclitaxel‐related neuropathy showed a trend toward increased incidence in patients treated with a platinum‐based first‐line, but not statistically significant difference was obseved (all‐grade neuropathy: 44% vs. 24%, respectively; p 0.14; data not shown). 3.3 Prognostic analysis The prognostic impact of pre‐treatment clinical and laboratory parameters on survival endpoints was explored in the entire population.

also in 53,322 other papers